The prevalence and use of antidepressant medication in pediatric cancer patients

Andrew Portteus, Naveed Ahmad, Daniel Tobey, Patrick Leavey

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: During the period of cancer diagnosis and active treatment, several small case series have revealed high rates of psychiatric difficulty in pediatric patients. However, due to the methodological limitations in these studies, it remains impossible to determine accurately the true prevalence of mood disorders in pediatric cancer patients receiving cancer treatment. To date, no study has reported rates of antidepressant treatment in this population. Objectives: The aims of this study were: (1) To determine the prevalence of the use of antidepressant medication (ADM) in children with cancer; (2) to identify a group of children being treated for cancer, that are likely to receive ADM, and who therefore may be eligible for a prospective observational or interventional clinical trial of depression during cancer therapy. Methods: We reviewed the medical records of 224 pediatric patients suspected for cancer in 2003 at the Children's Medical Center of Dallas. Of these, 6 proved non-oncologic and 2 were lost to follow up, leaving 216 charts for review. Results: Within 1 year of diagnosis, 29 patients (13%) had received a psychiatric consultation. Twenty-two patients (10.2%) received ADM within 1 year of cancer diagnosis. Children ≥ 12 years, children with acute lymphoblastic leukemia, and children receiving radiotherapy or opiate analgesics were more likely to receive ADM by multivariate analysis. Race, sex, bone marrow transplant, and surgery were not significantly associated with ADM use. Conclusions: The prevalence of ADM use in pediatric cancer patients (10.2%) was higher than the reported rates of depression (4-8%) and ADM treatment (1%) in the general pediatric population. Teenagers and those who received opiate analgesic medications during their cancer therapy represent a subgroup of children in whom further study of depression and cancer therapy may be valuable.

Original languageEnglish (US)
Pages (from-to)467-473
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number4
DOIs
StatePublished - Aug 2006

Fingerprint

Antidepressive Agents
Pediatrics
Neoplasms
Opiate Alkaloids
Therapeutics
Psychiatry
Analgesics
Depression
Lost to Follow-Up
Mood Disorders
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Population
Medical Records
Radiotherapy
Referral and Consultation
Multivariate Analysis
Bone Marrow
Clinical Trials
Transplants

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The prevalence and use of antidepressant medication in pediatric cancer patients. / Portteus, Andrew; Ahmad, Naveed; Tobey, Daniel; Leavey, Patrick.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 4, 08.2006, p. 467-473.

Research output: Contribution to journalArticle

@article{33ff4cffd94447e887bf50cabd1aa48b,
title = "The prevalence and use of antidepressant medication in pediatric cancer patients",
abstract = "Background: During the period of cancer diagnosis and active treatment, several small case series have revealed high rates of psychiatric difficulty in pediatric patients. However, due to the methodological limitations in these studies, it remains impossible to determine accurately the true prevalence of mood disorders in pediatric cancer patients receiving cancer treatment. To date, no study has reported rates of antidepressant treatment in this population. Objectives: The aims of this study were: (1) To determine the prevalence of the use of antidepressant medication (ADM) in children with cancer; (2) to identify a group of children being treated for cancer, that are likely to receive ADM, and who therefore may be eligible for a prospective observational or interventional clinical trial of depression during cancer therapy. Methods: We reviewed the medical records of 224 pediatric patients suspected for cancer in 2003 at the Children's Medical Center of Dallas. Of these, 6 proved non-oncologic and 2 were lost to follow up, leaving 216 charts for review. Results: Within 1 year of diagnosis, 29 patients (13{\%}) had received a psychiatric consultation. Twenty-two patients (10.2{\%}) received ADM within 1 year of cancer diagnosis. Children ≥ 12 years, children with acute lymphoblastic leukemia, and children receiving radiotherapy or opiate analgesics were more likely to receive ADM by multivariate analysis. Race, sex, bone marrow transplant, and surgery were not significantly associated with ADM use. Conclusions: The prevalence of ADM use in pediatric cancer patients (10.2{\%}) was higher than the reported rates of depression (4-8{\%}) and ADM treatment (1{\%}) in the general pediatric population. Teenagers and those who received opiate analgesic medications during their cancer therapy represent a subgroup of children in whom further study of depression and cancer therapy may be valuable.",
author = "Andrew Portteus and Naveed Ahmad and Daniel Tobey and Patrick Leavey",
year = "2006",
month = "8",
doi = "10.1089/cap.2006.16.467",
language = "English (US)",
volume = "16",
pages = "467--473",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - The prevalence and use of antidepressant medication in pediatric cancer patients

AU - Portteus, Andrew

AU - Ahmad, Naveed

AU - Tobey, Daniel

AU - Leavey, Patrick

PY - 2006/8

Y1 - 2006/8

N2 - Background: During the period of cancer diagnosis and active treatment, several small case series have revealed high rates of psychiatric difficulty in pediatric patients. However, due to the methodological limitations in these studies, it remains impossible to determine accurately the true prevalence of mood disorders in pediatric cancer patients receiving cancer treatment. To date, no study has reported rates of antidepressant treatment in this population. Objectives: The aims of this study were: (1) To determine the prevalence of the use of antidepressant medication (ADM) in children with cancer; (2) to identify a group of children being treated for cancer, that are likely to receive ADM, and who therefore may be eligible for a prospective observational or interventional clinical trial of depression during cancer therapy. Methods: We reviewed the medical records of 224 pediatric patients suspected for cancer in 2003 at the Children's Medical Center of Dallas. Of these, 6 proved non-oncologic and 2 were lost to follow up, leaving 216 charts for review. Results: Within 1 year of diagnosis, 29 patients (13%) had received a psychiatric consultation. Twenty-two patients (10.2%) received ADM within 1 year of cancer diagnosis. Children ≥ 12 years, children with acute lymphoblastic leukemia, and children receiving radiotherapy or opiate analgesics were more likely to receive ADM by multivariate analysis. Race, sex, bone marrow transplant, and surgery were not significantly associated with ADM use. Conclusions: The prevalence of ADM use in pediatric cancer patients (10.2%) was higher than the reported rates of depression (4-8%) and ADM treatment (1%) in the general pediatric population. Teenagers and those who received opiate analgesic medications during their cancer therapy represent a subgroup of children in whom further study of depression and cancer therapy may be valuable.

AB - Background: During the period of cancer diagnosis and active treatment, several small case series have revealed high rates of psychiatric difficulty in pediatric patients. However, due to the methodological limitations in these studies, it remains impossible to determine accurately the true prevalence of mood disorders in pediatric cancer patients receiving cancer treatment. To date, no study has reported rates of antidepressant treatment in this population. Objectives: The aims of this study were: (1) To determine the prevalence of the use of antidepressant medication (ADM) in children with cancer; (2) to identify a group of children being treated for cancer, that are likely to receive ADM, and who therefore may be eligible for a prospective observational or interventional clinical trial of depression during cancer therapy. Methods: We reviewed the medical records of 224 pediatric patients suspected for cancer in 2003 at the Children's Medical Center of Dallas. Of these, 6 proved non-oncologic and 2 were lost to follow up, leaving 216 charts for review. Results: Within 1 year of diagnosis, 29 patients (13%) had received a psychiatric consultation. Twenty-two patients (10.2%) received ADM within 1 year of cancer diagnosis. Children ≥ 12 years, children with acute lymphoblastic leukemia, and children receiving radiotherapy or opiate analgesics were more likely to receive ADM by multivariate analysis. Race, sex, bone marrow transplant, and surgery were not significantly associated with ADM use. Conclusions: The prevalence of ADM use in pediatric cancer patients (10.2%) was higher than the reported rates of depression (4-8%) and ADM treatment (1%) in the general pediatric population. Teenagers and those who received opiate analgesic medications during their cancer therapy represent a subgroup of children in whom further study of depression and cancer therapy may be valuable.

UR - http://www.scopus.com/inward/record.url?scp=33750586078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750586078&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.467

DO - 10.1089/cap.2006.16.467

M3 - Article

C2 - 16958571

AN - SCOPUS:33750586078

VL - 16

SP - 467

EP - 473

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -